2022 World Conference on Lung Cancer (ePosters)-EP08.02-078. Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)

EP08.02-078. Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)

Back to course

Pdf Summary

The document provides an update on the TRACES study, which is evaluating the safety and efficacy of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy. The study has enrolled 95 patients with a median age of around 61-62, and most patients are male. Baseline demographics and disease characteristics are similar between different parts of the study, and a significant number of patients have brain metastases.<br /><br />Pharmacokinetic data related to the active ingredient in trilaciclib, G1T28, is also presented. This data includes measurements of maximum concentration (Cmax) and area under the curve (AUC) in different patient populations from various studies.<br /><br />Trilaciclib is a CDK4/6 inhibitor approved by the FDA in 2021 to reduce chemotherapy-induced myelosuppression in ES-SCLC patients. The TRACES study consists of a safety run-in part and a double-blind, placebo-controlled part. Patients receive trilaciclib or placebo before chemotherapy, and the primary endpoints are pharmacokinetics, safety, and the duration of severe neutropenia.<br /><br />The document reports that trilaciclib was well tolerated in Chinese patients, with a similar pharmacokinetic profile to patients in Western countries. Administering trilaciclib before chemotherapy improved patient tolerability, reducing the duration and occurrence of severe neutropenia. Trilaciclib also decreased the use of granulocyte-colony stimulating factor (G-CSF) and the incidence of grade 3 or 4 hematologic toxicity.<br /><br />In first-line ES-SCLC patients, trilaciclib significantly reduced the duration of severe neutropenia compared to placebo and lowered the occurrence of severe and febrile neutropenia. Similar results were observed in second/third-line ES-SCLC patients.<br /><br />The study concludes that trilaciclib is well tolerated and improves chemotherapy tolerability in Chinese ES-SCLC patients. It provides myeloprotection by reducing the duration and occurrence of severe neutropenia and febrile neutropenia. Trilaciclib's pharmacokinetic profile in Chinese patients is comparable to non-Chinese patients, making it a promising option for improving outcomes in ES-SCLC patients.

Asset Subtitle

Ying Cheng

Meta Tag

Speaker Ying Cheng

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

TRACES study

trilaciclib

Chinese patients

extensive-stage small cell lung cancer

chemotherapy

pharmacokinetic data

G1T28

CDK4/6 inhibitor

neutropenia

myeloprotection